NCT04916431View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

mRNA-6231

Sterile frozen liquid dispersion for injection

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY